产品搜索 |
产品类别 |
推荐产品 |
叔丁基二甲基氯硅烷 |
2-氯-4,6-二甲基吡啶 |
2-溴-4,6-二甲基吡啶 |
6-氯苯并三氮唑-1,1,3,3- |
1,3-二苯基异苯并呋喃 |
培哚普利 |
9-(4-乙酰氧基-3-乙酰氧 |
嘧啶-5-硼酸 |
2-氯-3-硝基-4-甲基吡啶 |
7-氮杂吲哚 |
4-氮杂吲哚 |
5-氮杂吲哚 |
6-氮杂吲哚 |
7-azaoxindole |
6-azaoxindole |
4-叔丁基苯硼酸 |
D-氨基半乳糖盐酸盐 |
N-乙酰基-D-氨基半乳糖 |
溴代葡萄糖苷 |
利培酮 |
N-三氟乙酰基-L-赖氨酸 |
N2-(1-乙氧羰基-3-苯丙基 |
N2-[1-(S)-乙氧羰基-3-苯 |
3-氨基甲酰基苯硼酸 |
2,4-二氯-6-甲基嘧啶 |
N-(4-氨基丁基)-N-乙基异 |
AOP |
BOP |
4,4-二甲氧基三苯甲基 |
2-氯-1-甲基吡啶碘盐 |
HOTT |
TSTU |
1-(4-甲磺基)-3-硝基-1,2,4 |
TPTU |
2,4,6-三异丙基苯磺酰氯 |
TOTU |
TOTT |
TNTU |
TFFH |
TDBTU |
TCTU |
TCFH |
TBTU |
TATU |
N-Hydroxysulfosuccinimide sodi |
8-喹啉磺酰氯 |
PyCloP |
PYCLU |
PyBroP |
PyBOP |
|
产品展示 |
产品编号 |
产品名称 |
CAS No. |
含量 |
RovathinS10212 | Phosphonium, [(3'S)-1'-[(1,1-dimethylethoxy)carbonyl]-2-oxo[1,3'-bipyrrolidin]-3-yl]triphenyl-, bromide | 400045-51-4 | 95% |
RovathinS10213 | Butanoic acid, 2-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methylene]-3-methyl-, (2E)- | 387868-07-7 | 95% |
RovathinS10214 | Methanesulfonamide, 1,1,1-trifluoro-N-(1,2,3,4-tetrahydro-1-methyl-7-quinolinyl)- | 304690-95-7 | 95% |
RovathinS10215 | 1H-1-Benzazepine-1-acetic acid, 3-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, monohydrochloride, (3R)- | 215447-90-8 | 95% |
RovathinS10216 | 1H-1-Benzazepine-1-acetic acid, 3-[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, monohydrochloride, (3R)- | 215447-89-5 | 95% |
RovathinS10217 | 1-Piperidinecarboxylic acid, 3-hydroxy-4-[4-(phenylmethoxy)phenyl]-, 1,1-dimethylethyl ester, trans- | 188867-89-2 | 95% |
RovathinS10218 | Ethyl 6,8-difluoro-1,4-dihydro-1-(N-methylformamido)-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylate | 158585-86-5 | 95% |
RovathinS10219 | D-Homophenylalanine ethyl ester | 124044-66-2 | 95% |
RovathinS10220 | 1H-1-Benzazepine-1-acetic acid, 3-[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, monohydrochloride, (3S)- | 86541-77-7 | 95% |
RovathinS10221 | Benzenebutanoic acid, a-[[(1S)-1-carboxyethyl]amino]-, 1-ethyl ester, hydrochloride (1:1), (aS)- | 80828-26-8 | 95% |
RovathinS10222 | Ethyl (S)-2-amino-4-phenylbutyrate | 46460-23-5 | 95% |
RovathinS10223 | 1-Naphthalenamine, 5,8-dihydro- | 32666-56-1 | 95% |
RovathinS10224 | Bendamustin hydrochloride | 3543-75-7 | 95% |
RovathinS10225 | Hydroxylamine, O-[(2R)-2-pyrrolidinylmethyl]-, dihydrochloride | 952747-32-9 | 95% |
RovathinS10226 | N-[(3-Benzyloxypyridin-2-yl)methyl]formamide | 952024-31-6 | 95% |
RovathinS10227 | Carbamic acid, N-[(3S,5S)-5-methyl-3-piperidinyl]-, 1,1-dimethylethyl ester | 951163-61-4 | 95% |
RovathinS10228 | 6-Bromomethyl-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one | 911705-42-5 | 95% |
RovathinS10229 | 6-Bromo-1-(3-methoxypropyl)-3-methyl-1H-indazole | 865156-81-6 | 95% |
RovathinS10230 | 6-Chloromethyl-4-(3-methoxypropyl)-4H-benzo[1,4]oxazin-3-one | 857272-02-7 | 95% |
RovathinS10231 | 1H-Pyrano[3,4-f]indolizine-3,6,10(4H)-trione, 7-chloro-4-ethyl-7,8-dihydro-4-hydroxy-, (4S)- | 748799-31-7 | 95% |
RovathinS10232 | Propanedioic acid, 2-[(2E)-3-chloro-2-propen-1-yl]-2-(1-methylethyl)-, 1,3-dimethyl ester | 705259-97-8 | 95% |
RovathinS10233 | 6,7-Dihydro-5H-imidazo[1,5-a]pyridin-8-one | 426219-51-4 | 95% |
RovathinS10234 | 7-Oxabicyclo[4.1.0]hept-3-ene-3-carboxylic acid, 5-(1-ethylpropoxy)-, ethyl ester, (1S,5R,6S)- | 204254-96-6 | 95% |
RovathinS10235 | Propanedinitrile, 2-[2-[4-(1-methylethyl)phenyl]-1,1-dioxido-6-phenyl-4H-thiopyran-4-ylidene]- | 174493-15-3 | 95% |
RovathinS10236 | 2(3H)-Furanone, 5-[(1S,3S)-1-azido-3-(hydroxymethyl)-4-methylpentyl]dihydro-3-(1-methylethyl)-, (3S,5S)- | 173154-03-5 | 95% |
RovathinS10237 | D-Tryptophan, N-[N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl]- | 159634-94-3 | 95% |
RovathinS10238 | 1(4H)-Naphthalenone, 2-(1,1-dimethylethyl)-4-[3-(1,1-dimethylethyl)-4-oxo-1(4H)-naphthalenylidene]- | 148808-97-3 | 95% |
RovathinS10239 | 1,1-Dioxo-2-(4-methylphenyl)-6-phenyl-4-(dicyanomethylidene)thiopyran | 135215-38-2 | 95% |
RovathinS10240 | N,N-Dimethyl-3-(4-nitrophenoxy)propylamine | 91430-80-7 | 95% |
RovathinS10241 | 4-Bromo-7-hydroxyindan-1-one | 81945-13-3 | 95% |
|
|
|
|